Grand Opening Event to Highlight Cutting-Edge Bone Health and Strength Training Technology
BEVERLY HILLS, Calif., March 19, 2025 /PRNewswire/ — Tomorrow, OsteoStrong, the global leader in bone health and skeletal strength conditioning, will celebrate the grand opening of its Beverly Hills location. The new facility, located at 904 S. Robertson Blvd., marks the second OsteoStrong location for franchise partners Jayson Brightwell and Alessandro Rugge.
“This event marks an exciting milestone for OsteoStrong as we continue expanding our presence in key markets like Beverly Hills,” said Kyle Zagrodzky, founder and CEO of OsteoStrong. “We are incredibly proud of Jayson, Alessandro, Sarah, and Robert for their remarkable achievements. Their success exemplifies the power of our business model and the impact OsteoStrong is making in people’s lives.”
OsteoStrong is at the forefront of the wellness revolution, helping individuals improve bone density, strength, and overall health through its proprietary osteogenic loading technology. With a growing network of locations worldwide, the company continues to attract forward-thinking entrepreneurs dedicated to transforming lives through innovative wellness solutions.
The grand opening will take place March 20, 2025, from 5 to 7 p.m. PDT and will include a ribbon-cutting ceremony, facility tours, and a networking reception with franchisees, local health professionals, and wellness advocates.
Media representatives and community members are invited to attend and celebrate this milestone with OsteoStrong’s leadership and franchise owners.
About OsteoStrong®
OsteoStrong® is a science-backed, technology-driven system designed to improve bone density, strength, and overall skeletal health. With locations worldwide, OsteoStrong® helps people of all ages build stronger bones in a safe, efficient, and drug-free manner.
For more information about OsteoStrong®, visit www.osteostrong.me.
Media Contact
Interdependence Public Relations
392177@email4pr.com
949-259-6377 x 225
SOURCE OsteoStrong
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…